Abstract
Celecoxib, a specific inhibitor of cycloxygenase-2 (COX-2) is a poorly water-soluble nonsteroidal anti-inflammatory drug with relatively low bioavailability. The effect of β-cyclodextrin on the aqueous solubility and dissolution rate of celecoxib was investigated. The possibility of molecular arrangement of inclusion complexes of celecoxib and β-cyclodextrin were studied using molecular modeling and structural designing. The results offer a better correlation in terms of orientation of celecoxib inside the cyclodextrin cavity. Phase-solubility profile indicated that the solubility of celecoxib was significantly increased in the presence of β-cyclodextrin and was classified as AL-type, indicating the 1∶1 stoichiometric inclusion complexes. Solid complexes prepared by freeze drying, evaporation, and kneading methods were characterized using differential scanning calorimetry, powder x-ray diffractometry, and scanning electron microscopy. In vitro studies showed that the solubility and dissolution rate of celecoxib were significantly improved by complexation with β-cyclodextrin with respect to the drug alone. In contrast, freeze-dried complexes showed higher dissolution rate than the other complexes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib. Clin Pharmacokinet. 2000;38:225–242.
Simon LS, Lanza FL, Lipsky PE. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum. 1998;41:1591–1602.
Hubbard RC, Koepp RJ, Yu S. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study [abstract]. Arthritis Rheum. 1996;39:S226. Abstract 1188.
Hubbard RC, Mehlisch DR, Jasper DR. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model [Abstract]. J Invest Med. 1996;44: Abstract 293.
Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001;297:638–645.
FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442.
Szejtli J. Cyclodextrin Technology. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1988:81–83.
Loftson T, Brewster ME. Pharmaceutical applications of cyclodextrins: 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017–1025.
Connors KA. The stability of cyclodextrin complexes in solution. Chem Rev. 1997;97:1325–1357.
Uekema K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045–2076.
Stella VJ, Rajiwski RA. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res. 1997;14:556–567.
Uekama K, Hirayama F. Methods of investigating and preparing inclusion compounds. In: Duchene D, ed. Cyclodextrins and Their Industrial Uses. Paris, France: Editions de Santé; 1987:131–172.
Erden N, Celebi N. A study of the inclusion complex of naproxen with β-cyclodextrin. Int J Pharm. 1988;48:83–89.
Pop MM, Goubitz K, Borodi G, Bogdan M, De Ridder DJ, Peschar R, Schenk H. Crystal structure of the inclusion complex of betacyclodextrin with mefenamic acid from high-resolution synchrotron powder-diffraction data in combination with molecular-mechanics calculations. Acta Crystallogr B. 2002;58:1036–1043.
Bonmet P, Jaime C, Morin-Allory L. Alpha-, beta-, and gamma-Cyclodextrin dimers: Molecular modeling studies by molecular mechanics and molecular dynamics simulations. J Org Chem. 2001;66:689–692.
Ding HO, Karasawa N, Goddard WA. Atomic level simulations on a million particles: The cell multipole method for Coulomb and London nonbond interactions. J Chem Physiol. 1992;97(6):4309–4315.
Swope WC, Andersen HC. A computer simulation method for the calculation of equilibrium constants for the formation of physical clusters of molecules: Application to small water clusters. J Chem Physiol. 1982;76(1):637–649.
Higuchi T, Connors KA. Phase solubility diagram. Adv Anal Chem Instrum. 1965;4:117–212.
Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48–49.
Furlanetto S, Maestrelli F, Orlandini S, Pinzauti S, Mura P. Optimization of dissolution test precision for a ketoprofen oral extended-release product. J Pharm Biomed Anal. 2003;32:159–165.
Marques CH, Hadgraft J, Kellaway I. Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int J Pharm. 1990;63:259–266.
Uekama K, Hirayama F. Improvement of drug properties by cyclodextrin. In: Wermuth CG, ed. The Practice of Medicinal Chemistry. London, UK: Academic Press, 1996:793–825.
Szetli J. Medicinal applications of cyclodextrins. Med Res Rev. 1994;14:353–386.
Trapani G, Latrofa A, Franco M, et al. Complexation of Zolpiden with 2-hydroxypropyl-b-, methyl-b-, and 2-hydroxypropyl-g-cyclodextrin: Effect on aqueous solubility, dissolution rate and ataxic activity in rat. J Pharm Sci. 2000;89:1443–1451.
Author information
Authors and Affiliations
Additional information
Published: March 5, 2004
Rights and permissions
About this article
Cite this article
Reddy, M.N., Rehana, T., Ramakrishna, S. et al. β-cyclodextrin complexes of celecoxib: Molecular-modeling, characterization, and dissolution studies. AAPS J 6, 7 (2004). https://doi.org/10.1208/ps060107
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/ps060107